ViiV Healthcare Study Shows Success of Long-Acting HIV Injections Over Daily Pills

The ViiV’s Study Indicates the Importance of Choosing Suitable Drugs

Announcement

ViiV Healthcare, the expert specialist HIV company majorly owned by GSK, along with Shionogi and Pfizer as shareholders, introduced data from its phase 3b volition study, which elaborates that around 89% (n=129/145) of suitable treatment-naïve people living with HIV are seen to change to a long-term injectable combination of Vocabria and rekambys, which is a brand in Canada, Australia, and the US named cabenuva. The brand is putting an end to the daily Dovato (dolutegravir/lamivudine (DTG/3TC)). The other studies, according to the real-world data, bolster CAB+RPV LA’s effectiveness, covering a larger population.

Data Explanation at IAS 2025

ViiV partner and healthcare studies data highlighted encouraging options for treatment for HIV. Phase 3b volition study’s new data has evaluated the outcome of the treatment-naïve individuals who have gone through treatment with daily DTG/3TC pills and were offered an alternative to switch to CAB+RPV LA after the success of the viral end. The results of the study confirmed the findings according to the participation and evaluation, following the eligibility of the patients. The findings achieved tolerability and efficacy of DTG/3TC, which shows potential to be a choice and an end to other options.

Other Highlights

The execution of the studies showcased CAB LA for prep is considered and is very easy to approach for the main prevention groups. The EBONI and PILLAR studies show feasibility and acceptance of CAB LA for PrEP for mainly HIV prevention in vast populations, consisting of transgender men, black women, and men who have sex with men. The studies are spreading awareness and contributing largely to the healthcare market.

Views and Statements

Chief medical officer at ViiV Healthcare, MBChB, MFPM, Jean van Wyk said, “The data fetched from the VOLITION study showcase the various choices in HIV care that bolster encouragement in individuals to opt for medicines that also meet their everyday routine or needs. ViiV focused on long-term effective injectables for HIV, and we have three years of proven evidence by elaborating the impact of the company’s strong portfolio, which has a massive population and settings. The long-acting injectables enable options that provide tolerable, effective, enhanced adherence and a comfortable dosing schedule in comparison to the daily oral pills. These all factors are the major part of HIV treatment and prevention, and hence play a vital role in our ambition of putting an end to AIDS and HIV.”